Raguz J, Jerić I, Niault T, Nowacka J, Kuzet S, Rupp C, et al. Epidermal RAF prevents allergic skin disease. elife. 2016;5: pubmed publisher

Zeng L, Ehrenreiter K, Menon J, Menard R, Kern F, Nakazawa Y, et al. RKIP regulates MAP kinase signaling in cells with defective B-Raf activity. Cell Signal. 2013;25:1156-65 pubmed publisher

Leon K, Buj R, Lesko E, Dahl E, Chen C, Tangudu N, et al. DOT1L modulates the senescence-associated secretory phenotype through epigenetic regulation of IL1A. J Cell Biol. 2021;220: pubmed publisher

Gualtieri A, Kyprianou N, Gregory L, Vignola M, Nicholson J, Tan R, et al. Activating mutations in BRAF disrupt the hypothalamo-pituitary axis leading to hypopituitarism in mice and humans. Nat Commun. 2021;12:2028 pubmed publisher

Buj R, Leon K, Anguelov M, Aird K. Suppression of p16 alleviates the senescence-associated secretory phenotype. Aging (Albany NY). 2021;13:3290-3312 pubmed publisher

Schwartz J, Ma J, Lamprecht T, Walsh M, Wang S, Bryant V, et al. The genomic landscape of pediatric myelodysplastic syndromes. Nat Commun. 2017;8:1557 pubmed publisher

Yurugi H, Marini F, Weber C, David K, Zhao Q, Binder H, et al. Targeting prohibitins with chemical ligands inhibits KRAS-mediated lung tumours. Oncogene. 2017;36:4778-4789 pubmed publisher

Cherniack A, Shen H, Walter V, Stewart C, Murray B, Bowlby R, et al. Integrated Molecular Characterization of Uterine Carcinosarcoma. Cancer Cell. 2017;31:411-423 pubmed publisher

. Integrated genomic and molecular characterization of cervical cancer. Nature. 2017;543:378-384 pubmed publisher

Riverso M, Montagnani V, Stecca B. KLF4 is regulated by RAS/RAF/MEK/ERK signaling through E2F1 and promotes melanoma cell growth. Oncogene. 2017;36:3322-3333 pubmed publisher

Siljamäki E, Abankwa D. SPRED1 Interferes with K-ras but Not H-ras Membrane Anchorage and Signaling. Mol Cell Biol. 2016;36:2612-25 pubmed publisher

Kemper K, Krijgsman O, Kong X, Cornelissen Steijger P, Shahrabi A, Weeber F, et al. BRAF(V600E) Kinase Domain Duplication Identified in Therapy-Refractory Melanoma Patient-Derived Xenografts. Cell Rep. 2016;16:263-277 pubmed publisher

Chatelle C, Hövermann D, Muller A, Wagner H, Weber W, Radziwill G. Optogenetically controlled RAF to characterize BRAF and CRAF protein kinase inhibitors. Sci Rep. 2016;6:23713 pubmed publisher

Budina Kolomets A, Webster M, Leu J, Jennis M, Krepler C, Guerrini A, et al. HSP70 Inhibition Limits FAK-Dependent Invasion and Enhances the Response to Melanoma Treatment with BRAF Inhibitors. Cancer Res. 2016;76:2720-30 pubmed publisher

Bhargava A, Pelech S, Woodard B, Kerwin J, Maherali N. Registered report: RAF inhibitors prime wild-type RAF to activate the MAPK pathway and enhance growth. elife. 2016;5: pubmed publisher

Lenain C, Gusyatiner O, Douma S, van den Broek B, Peeper D. Autophagy-mediated degradation of nuclear envelope proteins during oncogene-induced senescence. Carcinogenesis. 2015;36:1263-74 pubmed publisher

Wiersma V, de Bruyn M, Wei Y, van Ginkel R, Hirashima M, Niki T, et al. The epithelial polarity regulator LGALS9/galectin-9 induces fatal frustrated autophagy in KRAS mutant colon carcinoma that depends on elevated basal autophagic flux. Autophagy. 2015;11:1373-88 pubmed publisher

Condelli V, Maddalena F, Sisinni L, Lettini G, Matassa D, Piscazzi A, et al. Targeting TRAP1 as a downstream effector of BRAF cytoprotective pathway: a novel strategy for human BRAF-driven colorectal carcinoma. Oncotarget. 2015;6:22298-309 pubmed

Ho J, Nadeem A, Rydström A, Puthia M, Svanborg C. Targeting of nucleotide-binding proteins by HAMLET--a conserved tumor cell death mechanism. Oncogene. 2016;35:897-907 pubmed publisher

Kugel C, Hartsough E, Davies M, Setiady Y, Aplin A. Function-blocking ERBB3 antibody inhibits the adaptive response to RAF inhibitor. Cancer Res. 2014;74:4122-32 pubmed publisher

van der Hoeven D, Cho K, Ma X, Chigurupati S, Parton R, Hancock J. Fendiline inhibits K-Ras plasma membrane localization and blocks K-Ras signal transmission. Mol Cell Biol. 2013;33:237-51 pubmed publisher

Yeh C, Bellon M, Wang F, Zhang H, Fu L, Nicot C. Loss of FBXW7-mediated degradation of BRAF elicits resistance to BET inhibitors in adult T cell leukemia cells. Mol Cancer. 2020;19:139 pubmed publisher

Palušová V, Renzova T, Verlande A, Vaclová T, Medková M, Cetlová L, et al. Dual Targeting of BRAF and mTOR Signaling in Melanoma Cells with Pyridinyl Imidazole Compounds. Cancers (Basel). 2020;12: pubmed publisher

Pathria G, Lee J, Hasnis E, Tandoc K, Scott D, Verma S, et al. Translational reprogramming marks adaptation to asparagine restriction in cancer. Nat Cell Biol. 2019;21:1590-1603 pubmed publisher

Ko T, Sharma R, Li S. Genome-wide screening identifies novel genes implicated in cellular sensitivity to BRAFV600E expression. Oncogene. 2019;: pubmed publisher

Hey F, Andreadi C, Noble C, Patel B, Jin H, Kamata T, et al. Over-expressed, N-terminally truncated BRAF is detected in the nucleus of cells with nuclear phosphorylated MEK and ERK. Heliyon. 2018;4:e01065 pubmed publisher

Uenaka T, Satake W, Cha P, Hayakawa H, Baba K, Jiang S, et al. In silico drug screening by using genome-wide association study data repurposed dabrafenib, an anti-melanoma drug, for Parkinson's disease. Hum Mol Genet. 2018;27:3974-3985 pubmed publisher

Ohanna M, Cerezo M, Nottet N, Bille K, Didier R, Béranger G, et al. Pivotal role of NAMPT in the switch of melanoma cells toward an invasive and drug-resistant phenotype. Genes Dev. 2018;32:448-461 pubmed publisher

Gao Y, Chang M, McKay D, Na N, Zhou B, Yaeger R, et al. Allele-Specific Mechanisms of Activation of MEK1 Mutants Determine Their Properties. Cancer Discov. 2018;8:648-661 pubmed publisher

Chen M, Wan L, Zhang J, Zhang J, Méndez L, Clohessy J, et al. Deregulated PP1α phosphatase activity towards MAPK activation is antagonized by a tumor suppressive failsafe mechanism. Nat Commun. 2018;9:159 pubmed publisher

Kong X, Kuilman T, Shahrabi A, Boshuizen J, Kemper K, Song J, et al. Cancer drug addiction is relayed by an ERK2-dependent phenotype switch. Nature. 2017;550:270-274 pubmed publisher

Nieto P, Ambrogio C, Esteban Burgos L, Gomez Lopez G, Blasco M, Yao Z, et al. A Braf kinase-inactive mutant induces lung adenocarcinoma. Nature. 2017;548:239-243 pubmed publisher

Yao Z, Yaeger R, Rodrik Outmezguine V, Tao A, Torres N, Chang M, et al. Tumours with class 3 BRAF mutants are sensitive to the inhibition of activated RAS. Nature. 2017;548:234-238 pubmed publisher

Takahashi M, Li Y, Dillon T, Kariya Y, Stork P. Phosphorylation of the C-Raf N Region Promotes Raf Dimerization. Mol Cell Biol. 2017;37: pubmed publisher

Carroll B, Nelson G, Rabanal Ruiz Y, Kucheryavenko O, Dunhill Turner N, Chesterman C, et al. Persistent mTORC1 signaling in cell senescence results from defects in amino acid and growth factor sensing. J Cell Biol. 2017;216:1949-1957 pubmed publisher

Wei W, Sun Z, Shen C, Song H, Zhang X, Qiu Z, et al. Obatoclax and LY3009120 Efficiently Overcome Vemurafenib Resistance in Differentiated Thyroid Cancer. Theranostics. 2017;7:987-1001 pubmed publisher

van Veen J, Pringle D, McMahon M. P2A-Fluorophore Tagging of BRAF Tightly Links Expression to Fluorescence In Vivo. PLoS ONE. 2016;11:e0157661 pubmed publisher

Manchado E, Weissmueller S, Morris J, Chen C, Wullenkord R, Lujambio A, et al. A combinatorial strategy for treating KRAS-mutant lung cancer. Nature. 2016;534:647-51 pubmed

Bhargava A, Anant M, Mack H. Registered report: Kinase-dead BRAF and oncogenic RAS cooperate to drive tumor progression through CRAF. elife. 2016;5: pubmed publisher

Lakshmanan A, Scarberry D, Green J, Zhang X, Selmi Ruby S, Jhiang S. Modulation of thyroidal radioiodide uptake by oncological pipeline inhibitors and Apigenin. Oncotarget. 2015;6:31792-804 pubmed publisher

Karreth F, Reschke M, Ruocco A, Ng C, Chapuy B, Léopold V, et al. The BRAF pseudogene functions as a competitive endogenous RNA and induces lymphoma in vivo. Cell. 2015;161:319-32 pubmed publisher

Kaplon J, Zheng L, Meissl K, Chaneton B, Selivanov V, Mackay G, et al. A key role for mitochondrial gatekeeper pyruvate dehydrogenase in oncogene-induced senescence. Nature. 2013;498:109-12 pubmed publisher

Le K, Blomain E, Rodeck U, Aplin A. Selective RAF inhibitor impairs ERK1/2 phosphorylation and growth in mutant NRAS, vemurafenib-resistant melanoma cells. Pigment Cell Melanoma Res. 2013;26:509-17 pubmed publisher

Basile K, Aplin A. Downregulation of Noxa by RAF/MEK inhibition counteracts cell death response in mutant B-RAF melanoma cells. Am J Cancer Res. 2012;2:726-35 pubmed

Kaplan F, Kugel C, Dadpey N, Shao Y, Abel E, Aplin A. SHOC2 and CRAF mediate ERK1/2 reactivation in mutant NRAS-mediated resistance to RAF inhibitor. J Biol Chem. 2012;287:41797-807 pubmed publisher

Subramanian R, Yamakawa A. Combination therapy targeting Raf-1 and MEK causes apoptosis of HCT116 colon cancer cells. Int J Oncol. 2012;41:1855-62 pubmed publisher

Shao Y, Aplin A. BH3-only protein silencing contributes to acquired resistance to PLX4720 in human melanoma. Cell Death Differ. 2012;19:2029-39 pubmed publisher

Torti V, Wojciechowicz D, Hu W, John Baptiste A, Evering W, Troche G, et al. Epithelial tissue hyperplasia induced by the RAF inhibitor PF-04880594 is attenuated by a clinically well-tolerated dose of the MEK inhibitor PD-0325901. Mol Cancer Ther. 2012;11:2274-83 pubmed publisher

Rodrigues L, Chung Y, Al Saffar N, Sharp S, Jackson L, Banerji U, et al. Effects of HSP90 inhibitor 17-allylamino-17-demethoxygeldanamycin (17-AAG) on NEU/HER2 overexpressing mammary tumours in MMTV-NEU-NT mice monitored by Magnetic Resonance Spectroscopy. BMC Res Notes. 2012;5:250 pubmed publisher

Wang Z, Feng Y, Bardeesy N, Bardessy N, WONG K, Liu X, et al. Temporal dissection of K-ras(G12D) mutant in vitro and in vivo using a regulatable K-ras(G12D) mouse allele. PLoS ONE. 2012;7:e37308 pubmed publisher

Flockhart R, Webster D, Qu K, Mascarenhas N, Kovalski J, Kretz M, et al. BRAFV600E remodels the melanocyte transcriptome and induces BANCR to regulate melanoma cell migration. Genome Res. 2012;22:1006-14 pubmed publisher

Suram A, Kaplunov J, Patel P, Ruan H, Cerutti A, Boccardi V, et al. Oncogene-induced telomere dysfunction enforces cellular senescence in human cancer precursor lesions. EMBO J. 2012;31:2839-51 pubmed publisher

Piscazzi A, Costantino E, Maddalena F, Natalicchio M, Gerardi A, Antonetti R, et al. Activation of the RAS/RAF/ERK signaling pathway contributes to resistance to sunitinib in thyroid carcinoma cell lines. J Clin Endocrinol Metab. 2012;97:E898-906 pubmed publisher

Giles N, Pavey S, Pinder A, Gabrielli B. Multiple melanoma susceptibility factors function in an ultraviolet radiation response pathway in skin. Br J Dermatol. 2012;166:362-71 pubmed publisher

Klein R, Higgins P. A switch in RND3-RHOA signaling is critical for melanoma cell invasion following mutant-BRAF inhibition. Mol Cancer. 2011;10:114 pubmed publisher

Bommarito A, Richiusa P, Carissimi E, Pizzolanti G, Rodolico V, Zito G, et al. BRAFV600E mutation, TIMP-1 upregulation, and NF-κB activation: closing the loop on the papillary thyroid cancer trilogy. Endocr Relat Cancer. 2011;18:669-85 pubmed publisher

Hömig Hölzel C, van Doorn R, Vogel C, Germann M, Cecchini M, Verdegaal E, et al. Antagonistic TSC22D1 variants control BRAF(E600)-induced senescence. EMBO J. 2011;30:1753-65 pubmed publisher

Little A, Balmanno K, Sale M, Newman S, Dry J, Hampson M, et al. Amplification of the driving oncogene, KRAS or BRAF, underpins acquired resistance to MEK1/2 inhibitors in colorectal cancer cells. Sci Signal. 2011;4:ra17 pubmed publisher

Karki P, Li X, Schrama D, Fliegel L. B-Raf associates with and activates the NHE1 isoform of the Na+/H+ exchanger. J Biol Chem. 2011;286:13096-105 pubmed publisher

López Vicente L, Pons B, Coch L, Teixidó C, Hernandez Losa J, Armengol G, et al. RSK4 inhibition results in bypass of stress-induced and oncogene-induced senescence. Carcinogenesis. 2011;32:470-6 pubmed publisher

Valluet A, Hmitou I, Davis S, Druillennec S, Larcher M, Laroche S, et al. B-raf alternative splicing is dispensable for development but required for learning and memory associated with the hippocampus in the adult mouse. PLoS ONE. 2010;5:e15272 pubmed publisher

Smith F, Langeberg L, Cellurale C, Pawson T, Morrison D, Davis R, et al. AKAP-Lbc enhances cyclic AMP control of the ERK1/2 cascade. Nat Cell Biol. 2010;12:1242-9 pubmed publisher

Adams D, Wang Y, Mak P, Chyba J, Shalizi O, Matzen J, et al. Cellular Ser/Thr-kinase assays using generic peptide substrates. Curr Chem Genomics. 2008;1:54-64 pubmed publisher

Shu F, Ramineni S, Hepler J. RGS14 is a multifunctional scaffold that integrates G protein and Ras/Raf MAPkinase signalling pathways. Cell Signal. 2010;22:366-76 pubmed publisher

Noble C, Mercer K, Hussain J, Carragher L, Giblett S, Hayward R, et al. CRAF autophosphorylation of serine 621 is required to prevent its proteasome-mediated degradation. Mol Cell. 2008;31:862-72 pubmed publisher

Provot S, Nachtrab G, Paruch J, Chen A, Silva A, Kronenberg H. A-raf and B-raf are dispensable for normal endochondral bone development, and parathyroid hormone-related peptide suppresses extracellular signal-regulated kinase activation in hypertrophic chondrocytes. Mol Cell Biol. 2008;28:344-57 pubmed

Nagao S, Nishii K, Yoshihara D, Kurahashi H, Nagaoka K, Yamashita T, et al. Calcium channel inhibition accelerates polycystic kidney disease progression in the Cy/+ rat. Kidney Int. 2008;73:269-77 pubmed

Granas C, Lundholt B, Loechel F, Pedersen H, Bjørn S, Linde V, et al. Identification of RAS-mitogen-activated protein kinase signaling pathway modulators in an ERF1 redistribution screen. J Biomol Screen. 2006;11:423-34 pubmed

McPhillips F, Mullen P, MacLeod K, Sewell J, Monia B, Cameron D, et al. Raf-1 is the predominant Raf isoform that mediates growth factor-stimulated growth in ovarian cancer cells. Carcinogenesis. 2006;27:729-39 pubmed

Michaloglou C, Vredeveld L, Soengas M, Denoyelle C, Kuilman T, van der Horst C, et al. BRAFE600-associated senescence-like cell cycle arrest of human naevi. Nature. 2005;436:720-4 pubmed